NVCR: NovoCure Ltd.
About
NovoCure Ltd. is an oncology company which engages in the development, manufacture, and commercialization of Optune for the treatment of a variety of solid tumors. Its platform is called the Tumor Treating Field which uses electric fields tuned to specific frequencies to disrupt solid tumor cancer cell division. The company was founded by Yoram Palti in 2000 and is headquartered in St. Helier, Jersey.
Current Value
$16.261 Year Return
Current Value
$16.261 Year Return
Key Details
Market Cap
$1.78B
P/E Ratio
-11.82
1Y Stock Return
34.75%
1Y Revenue Growth
14.63%
Dividend Yield
0.00%
Price to Book
4.9
Strategies that include NVCR
Stock's related to NVCR
Correlated Stocks
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| BEAM | 49.45% | $2.09B | -9.52% | 0.00% |
| NTLA | 43.58% | $1.44B | -50.35% | 0.00% |
| KN | 43.55% | $1.60B | +12.19% | 0.00% |
| HSII | 43.41% | $914.74M | +64.66% | 1.35% |
| DNLI | 43.01% | $3.50B | +33.66% | 0.00% |
| CWH | 42.92% | $1.36B | +5.90% | 2.22% |
| PLRX | 42.52% | $778.32M | -9.55% | 0.00% |
| GH | 42.11% | $3.79B | +33.86% | 0.00% |
| LOCO | 42.00% | $361.37M | +39.70% | 0.00% |
| KIDS | 41.78% | $588.93M | -24.59% | 0.00% |
| BLDP | 41.63% | $398.23M | -61.89% | 0.00% |
| DLX | 41.14% | $1.01B | +24.44% | 5.30% |
| PSFE | 40.90% | $1.06B | +42.18% | 0.00% |
| KFRC | 40.86% | $1.10B | -8.71% | 0.66% |
| MATW | 40.65% | $731.28M | -31.68% | 4.06% |
| WRBY | 40.50% | $2.75B | +120.67% | 0.00% |
| BLFS | 40.32% | $1.04B | +64.64% | 0.00% |
| FLGT | 39.97% | $519.98M | -37.82% | 0.00% |
| PLOW | 39.87% | $572.50M | -7.57% | 4.79% |
| GNL | 39.82% | $1.69B | -16.46% | 16.20% |
Uncorrelated Stocks
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| FF | -0.01% | $227.57M | +21.57% | 4.55% |
| TEO | 0.02% | $1.69B | +87.97% | 0.00% |
| CYCN | 0.08% | $4.77M | -16.19% | 0.00% |
| DK | 0.11% | $1.14B | -34.04% | 5.64% |
| MMC | -0.20% | $108.41B | +10.89% | 1.37% |
| KRRO | 0.20% | $436.84M | +20.68% | 0.00% |
| STG | 0.20% | $35.67M | +7.92% | 0.00% |
| CLX | -0.27% | $20.81B | +20.66% | 2.88% |
| CLMT | 0.32% | $1.79B | +35.14% | 0.00% |
| QNTM | 0.33% | $9.19M | -94.36% | 0.00% |
| WTW | -0.39% | $30.98B | +26.60% | 1.13% |
| PDD | -0.40% | $163.43B | +0.29% | 0.00% |
| LX | 0.41% | $446.80M | +57.07% | 4.21% |
| NMM | -0.41% | $1.58B | +126.51% | 0.38% |
| EDR | 0.42% | $9.01B | +19.26% | 0.82% |
| MNOV | -0.47% | $93.19M | +2.15% | 0.00% |
| EDU | -0.48% | $9.06B | -22.20% | 0.00% |
| PRT | 0.51% | $48.72M | -16.56% | 10.33% |
| FCN | 0.58% | $7.10B | -10.74% | 0.00% |
| MCS | 0.58% | $669.85M | +49.35% | 1.28% |
Inversely Correlated Stocks
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| MCK | -12.83% | $78.15B | +35.51% | 0.42% |
| COR | -11.03% | $47.48B | +21.20% | 0.86% |
| CBOE | -10.39% | $21.46B | +15.84% | 1.11% |
| PGR | -10.37% | $149.10B | +57.29% | 0.45% |
| SOC | -9.63% | $1.93B | +74.70% | 0.00% |
| ACGL | -9.54% | $36.00B | +16.84% | 0.00% |
| HUSA | -9.37% | $16.69M | -11.56% | 0.00% |
| LPTH | -8.94% | $62.27M | +33.05% | 0.00% |
| COP | -8.91% | $130.16B | -1.63% | 2.59% |
| NNE | -8.86% | $833.66M | +531.50% | 0.00% |
| TPST | -8.01% | $37.75M | -77.59% | 0.00% |
| PG | -7.53% | $402.15B | +14.14% | 2.33% |
| ROOT | -6.73% | $1.53B | +972.93% | 0.00% |
| WRB | -6.57% | $22.94B | +29.98% | 0.69% |
| NEUE | -6.46% | $40.93M | -34.13% | 0.00% |
| CYD | -6.33% | $364.46M | -2.94% | 4.26% |
| CAH | -6.12% | $28.64B | +12.14% | 1.70% |
| UUU | -6.09% | $4.97M | -41.89% | 0.00% |
| IMO | -5.98% | $39.72B | +31.84% | 2.23% |
| OCX | -5.68% | $42.93M | -36.09% | 0.00% |
ETF's related to NVCR
News
Yahoo
NovoCure ( (NVCR) ) just unveiled an announcement. Novocure reported a robust third quarter in 2024, with net revenues surging by 22% to $155 million, driven by successful market expansions and improved approval rates in the U.S. The company also celebrated FDA approval of Optune Lua for metastatic non-small cell lung cancer, marking a significant milestone. Additionally, management transitions are underway with Christoph Brackmann taking over as CFO from January 2025, as Novocure aims to sustai
Yahoo
NovoCure Ltd (NVCR) reports a 22% revenue increase and FDA approvals, while navigating executive changes and reimbursement challenges.
Yahoo
NVCR earnings call for the period ending September 30, 2024.
Yahoo
NovoCure (NVCR) delivered earnings and revenue surprises of 17.65% and 7.60%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
SeekingAlpha
NovoCure Limited (NASDAQ:NVCR) Q3 2024 Earnings Conference Call October 30, 2024 8:00 AM ETCompany ParticipantsIngrid Goldberg - IRBill Doyle -...
Yahoo
ST. HELIER, Jersey (AP) — NovoCure Ltd. (NVCR) on Wednesday reported a loss of $30.6 million in its third quarter. The St. Helier, Jersey-based company said it had a loss of 28 cents per share.
Disclaimer
Information on this page is obtained from our data provider, Xignite, an unaffiliated third party. Double believes the information shown here is reliable, but has not been verified and there is no guarantee that the information is accurate. We also show information based on calculations performed by Double using data from our provider. Double believes this information is reliable, but has not verified the data and there is no guarantee that the calculations are accurate.